[][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79932]], camposKey:0049-3848 2023-12-01 Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer133137, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79933]], camposKey:0960-8931 2023-10-01 Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study388397, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79934]], camposKey:0169-5002 2023-04-01 Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer116122, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79935]], camposKey:1699-048X 2023-03-01 SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry768775, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79936]], camposKey:0028-4793 2023-01-01 Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer504513, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79937]], camposKey:0213-9111 2022-11-01 Representativeness of the Spanish Thoracic Tumour Registry. Comparison of sociodemographic data with other national registries Representatividad del Registro de Tumores Torácicos de España. Comparación de datos sociodemográficos con otros registros nacionales540545, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79939]], camposKey:0169-5002 2022-07-01 A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9¿15 PROMISE-meso phase III trial7783, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79940]], camposKey:1699-048X 2022-07-01 Correction to: SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021) (Clinical and Translational Oncology, (2022), 24, 4, (712-723), 10.1007/s12094-022-02802-1)00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79938]], camposKey:1741-0541 2022-07-01 Targeting molecular alterations in non-small-cell lung cancer: What's next?341359, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79941]], camposKey:0959-8049 2022-05-01 Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations142148, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79942]], camposKey:1699-048X 2022-04-01 SEOM clinical guideline emesis (2021)712723, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79943]], camposKey:1471-2407 2021-12-01 Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79944]], camposKey:1556-0864 2021-11-01 A New Pretreatment Mesothelioma Risk Score: Integrating Clinical and Molecular Factors for Predicting Outcomes in Malignant Pleural Mesothelioma17821784, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79945]], camposKey:2218-6751 2021-10-01 Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study39023911, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79946]], camposKey:1932-6203 2021-06-01 Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=58731]], camposKey:0365-6691 2021-06-01 Intraocular metastasis as a systemic presentation of neuroendocrine differentiation of prostate carcinoma Metástasis intraocular como presentación sistémica de un adenocarcinoma de próstata con diferenciación neuroendocrina332336, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79947]], camposKey:1699-048X 2021-05-01 SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)980987, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79948]], camposKey:0732-183X 2021-02-20 Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)586598, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=59222]], camposKey:0213-4853 2021-01-01 SMART syndrome Síndrome de SMART9092, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65464]], camposKey:0009-739X 2021-01-01 Spanish Society of Thoracic Surgery (SECT) consensus document. Long-term follow-up for operated patients with lung cancer Documento de consenso de la Sociedad Española de Cirugía Torácica (SECT). Seguimiento a largo plazo de los pacientes operados de cáncer de pulmón00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79949]], camposKey:0923-7534 2020-12-01 A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial17341745, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79950]], camposKey:2059-7029 2020-11-19 Lung cancer symptoms at diagnosis: Results of a nationwide registry study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79951]], camposKey:1877-7821 2020-08-01 Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=50391]], camposKey:0300-2896 2019-01-01 Association Between Idiopathic Pulmonary Fibrosis and Lung Cancer Asociación entre fibrosis pulmonar idiopática y neoplasia pulmonar00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79953]], camposKey:2149-2530 2019-01-01 Forearm metastases as unsuspected first manifestations of lung adenocarcinoma6668, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79952]], camposKey:2218-6751 2019-01-01 Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)461475, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79954]], camposKey:0300-2896 2018-07-01 Skeletal Muscle Metastasis: An Uncommon Finding in Lung Cancer Metástasis musculoesqueléticas: hallazgo infrecuente asociado al cáncer de pulmón390391, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79955]], camposKey:0903-1936 2018-05-01 Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79956]], camposKey:1699-048X 2017-12-01 Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database15371542, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79957]], camposKey:0960-8931 2016-01-01 Treatment patterns of adjuvant interferon-¿2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study278283, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79958]], camposKey:1134-248X 2015-01-01 Prevalence of pain in cancer patients: breakthrough pain Prevalencia del dolor en enfermos oncológicos. Dolor irruptivo29, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79959]], camposKey:1885-740X 2009-08-13 New targeted therapies in head and neck cancer3543][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][]